Israel-Medical-Healthcare

[genisi]

Last time they spoke about their nucleoside CF102, was August 19, 2007. They said they completed the preclinical trials in collaboration with Temple University in Philadelphia which showed that CF102 is also active against the hepatitis virus. They want to start clinical trials by the end of the year.

I am going to meet with the company after the holidays, will add any more useful data provided at the presentation.